ONS USE IN COLON CANCER

This retrospective observational cohort study examined oral nutritional supplement (ONS) use and associated factors in patients receiving adjuvant mFOLFOX6 chemotherapy after curative surgery for stage III colon cancer. Medical and routine nutrition follow-up records from Osmaniye Training and Research Hospital between January 2021 and January 2026 were reviewed. The study included 362 patients prescribed ONS. The main outcomes were ONS non-initiation or early discontinuation and failure to meet a study-defined consumption criterion among ONS users. Demographic, clinical, nutritional, and psychosocial factors associated with these outcomes were evaluated.

Inclusion Criteria: * Age 18 years or older. * Histopathologically confirmed stage III colon adenocarcinoma according to the eighth edition of the AJCC TNM classification. * Previous curative surgery for colon cancer. * Receipt of adjuvant mFOLFOX6 chemotherapy. * Prescription of oral nutritional supplements (ONS) during adjuvant chemotherapy. * At least three months of clinical and Nutrition Outpatient Clinic follow-up. * Complete medical and nutritional records for the variables required for analys Exclusion Criteria: * Pregnancy or postpartum status. * Receipt of neoadjuvant or palliative treatment. * Receipt of chemotherapy regimens other than mFOLFOX6. * Active second malignancy. * Dementia or a history of cerebrovascular disease. * Dysphagia, previous upper gastrointestinal surgery, or food allergy precluding safe ONS use. * Additional major surgery performed during colectomy. * Preoperative ONS use. * ONS usage that could not be assessed from available records. * Missing follow-up information or analytical data.